Literature DB >> 31727271

Recent excitements in the study of the CAM assay.

Fuyuhiko Tamanoi1.   

Abstract

Chick chorioallantoic membrane (CAM) assay provides a convenient and versatile model for the study of tumor formation, angiogenesis and metastasis. While the assay has been used for more than 100 years, the CAM assay has recently received renewed interest. One of the recent interests comes from the development of Precision Medicine in cancer therapy. The idea is to develop treatments that are tailor-made for each individual patient. For this to happen, patient-derived tumor models are critical and the CAM assay can make significant contribution. The other development concerns various applications of the CAM assay. Using this assay, various reagents have been identified. This includes sensitizers for radiation therapy and photodynamic therapy. We also discuss boron neutron capture therapy (BNCT) that is based on the splitting of boron-10 upon exposure to neutron beam. Recently, various boron-10 reagents have been developed and they can be examined for their efficacy for BNCT therapy using the CAM assay.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Applications; Boron neutron capture therapy; CAM assay; Mechanism of tumor formation; Number of publications; Patient-derived models; Precision medicine

Mesh:

Year:  2019        PMID: 31727271     DOI: 10.1016/bs.enz.2019.10.002

Source DB:  PubMed          Journal:  Enzymes        ISSN: 1874-6047


  3 in total

Review 1.  Angiogenesis in the Avian Embryo Chorioallantoic Membrane: A Perspective on Research Trends and a Case Study on Toxicant Vascular Effects.

Authors:  Warren Burggren; Maria Rojas Antich
Journal:  J Cardiovasc Dev Dis       Date:  2020-12-05

2.  Downregulation of m6 A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness.

Authors:  Catarina Guimarães-Teixeira; João Lobo; Vera Miranda-Gonçalves; Daniela Barros-Silva; Cláudia Martins-Lima; Sara Monteiro-Reis; José Pedro Sequeira; Isa Carneiro; Margareta P Correia; Rui Henrique; Carmen Jerónimo
Journal:  Mol Oncol       Date:  2022-03-24       Impact factor: 7.449

3.  Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications.

Authors:  Ghadir Kalot; Amélie Godard; Benoît Busser; Jacques Pliquett; Mans Broekgaarden; Vincent Motto-Ros; Karl David Wegner; Ute Resch-Genger; Ulli Köster; Franck Denat; Jean-Luc Coll; Ewen Bodio; Christine Goze; Lucie Sancey
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.